[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:autoantibody":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Autoantibody",10,6,[8,16,23,30,36,42,48,55,61,68],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07673744","A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)",[12],"Phase 2","RECRUITING","2026-08-26T02:19:13.549512Z","2026-07-05T03:45:20.432625Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07661056","Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease",[20],"Phase 3","2026-08-26T02:18:15.214990Z","2026-07-05T03:45:20.259405Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06626919","A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases",[27],"Phase 1","2026-08-26T02:15:09.079045Z","2026-05-05T02:43:28.963761Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07219563","Alnuctamab for Refractory SLE (LATTE Study)",[27],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.475692Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04097561","Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)",[27],"2026-08-26T02:18:40.612983Z","2026-05-05T02:35:31.916745Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT02234388","Undifferentiated Connective Tissue Disease Registry",[],"2026-08-26T02:19:02.550788Z","2026-05-13T02:55:06.091190Z",{"nct_id":49,"title":50,"phases":51,"status":52,"updated_at":53,"content_modified":54},"NCT07674745","Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis",[12],"NOT_YET_RECRUITING","2026-08-26T02:17:41.695983Z","2026-07-05T03:45:20.434634Z",{"nct_id":56,"title":57,"phases":58,"status":52,"updated_at":59,"content_modified":60},"NCT06984341","A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)",[27],"2026-08-03T02:51:12.602181Z","2026-05-05T02:43:29.728328Z",{"nct_id":62,"title":63,"phases":64,"status":65,"updated_at":66,"content_modified":67},"NCT00704626","Serum Auto-Antibodies in Neurological Diseases",[],"ENROLLING_BY_INVITATION","2026-08-26T02:19:25.538428Z","2026-06-16T05:54:07.944323Z",{"nct_id":69,"title":70,"phases":71,"status":72,"updated_at":73,"content_modified":74},"NCT06980805","A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:02:58.488119Z","2026-05-05T02:43:26.740249Z"]